¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Comtrex Nighttime Maximum Strength Cold and Flu Relief"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • half and half nail
    ¹Ý°ú¹Ý¼Õ¹ßÅé
  • incision and drainage
    1. Àý°³¹è³ó(¼ú) 2. Àý°³¹è¾×(¼ú)
  • intake and output record
    ¼·Ãë¹è¼³·®±â·Ï
  • kidney ureter and bladder
    ÄáÆÏ¿ä°ü¹æ±¤´Ü¼øÃÔ¿µ
  • law of weights and measures
    °è·®¹ý
  • left and right handedness
    ¾ç¼ÕÀâÀÌ
  • maternal and child health
    ¸ðÀÚº¸°Ç
  • maternity and infant hygiene
    ¸ð¼º¿µ¾ÆÀ§»ý
  • picture archiving and communicating system
    ¿µ»óÀúÀå¹×Àü¼Ûü°è
  • perfusion and diffusion imaging
    °ü·ùÈ®»ê¿µ»ó
  • salt-and-pepper fundus
    ÈÄÃ߼ұݸð¾ç¾ÈÀú, ÈÄÃ߼ұݸð¾ç´«¹Ù´Ú
  • wear and tear dermatitis
    ¹Ýº¹ÀÚ±ØÇǺο°
  • maximum
    ÃÖ´ë
  • maximum absorption
    ÃÖ´ëÈí¼ö
  • maximum acceptable daily intake
    ÀÏÀϼ·ÃëÃÖ´ëÇã¿ë·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • yield strength
    Ç׺¹¼¼±â
  • anxious and fearful personality
    ºÒ¾È°øÆ÷ÀΰÝ
  • arch and band appliance
    Ȱ¶ìÀåÄ¡
  • split pin and tube attachment
    À¯ÃʺÐÇÒÇÕÁ¤
  • babbling and lalling stage
    ¿Ë¾ËÀ̽ñâ
  • bilateral cleft lip and palate
    ¾çÂÊÀÔ¼úÀÔõÀå°¥¸²Áõ
  • bread and butter pericarditis
    »§¹öÅ͸ð¾ç½ÉÀ帷¿°
  • dilatation and curettage
    ÀڱøñÈ®Àå±Ü¾î³¿¼ú, °æ°üÈ®ÀåÀÚ±Ã¼ÒÆÄ¼ú
  • exudative chronic discoid and lichenoid dermatitis
    »ïÃ⸸¼º¿ø¹Ýż±ÇǺο°
  • foot-and-mouth disease
    ÀԹ߱Áº´, ±¸Á¦¿ª
  • incision and drainage
    Àý°³¹è³ó
  • wear and tear dermatitis
    ¹Ýº¹ÀÚ±ØÇǺο°
  • embryonal and botryoid rhabdomyosarcoma
    ¹è¾ÆÆ÷µµÈ¾¹®±ÙÀ°Á¾
  • salt-and-pepper fundus
    ÈÄÃ߼ұݸð¾ç¾ÈÀú, ÈÄÃ߼ұݸð¾ç´«¹Ù´Ú
  • left and right handedness
    ¾ç¼ÕÀâÀÌ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • General anesthesia, reticular activating system and.
    Àü½Å¸¶Ãë(îïãóئö­), ¸Á»óüȰ¼ºÈ­°è(ØÑßÒô÷üÀàõûùͧ)
  • Gravity, cardiac output and
    Áß·Â(ñìÕô), ½É¹ÚÃâ·®(ãýÚÑõóÕá)
  • KUB= kidney, ureter and bladder
    ½Å-´¢°ü-¹æ±¤ ´Ü¼øÃÔ¿µ
  • Kell antigen and antibody
    ÄÌÇ׿øÇ×ü
  • PACS (picture archiving and communicating system)
    ÆÑ½º, ¿µ»ó ÀúÀå ¹× Àü¼Û ü°è
  • PANSS=Positive and Negative Syndrome Scale
    ¾ç¼º À½¼º ÁõÈıº ôµµ
  • SADS, Schedule for Affective Disorders and Schizophrenia
    Á¤µ¿Àå¾Ö¿Í Á¤½ÅºÐ¿­º´ÀÇ Áø´ÜÀ» À§ÇÑ ¸ñ·Ï
  • SOFAS, Social and Occupational Functioning Assessment Scale
    »çȸ-Á÷¾÷±â´ÉÆò°¡Ã´µµ
  • SONAR(Sound Navigation and Ranging)
    ¼Ò³ª
  • acute and late normal tissue effects
    Á¤»óÁ¶Á÷ ±Þ¼º¿µÇâ, Á¤»óÁ¶Á÷ ¸¸¼º ¿µÇâ
  • ambient temperature and pressure saturated with water vapor =ATP
    ½Ç¿Â´ë±â¾Ð ¼öÁõ±â Æ÷È­»óÅÂ
  • american society of therapeutic radiology and onco
    logy (ASTRO) ¹Ì±¹¹æ»ç¼±Á¾¾çÇÐȸ
  • aphthous fever =foot and mouth disease
    ¾ÆÇÁŸ¼º¿­(¡­æð).
  • glioma of optic nerve and chiasm
    ½Ã½Å°æ±³Â÷ ±³¼¼Æ÷Á¾.
  • glycerin and potash solution
    ±Û¸®¼¼¸° Ä®·ý¾×.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • low-ionic--strength salt solution =LISS
    ÀúÀ̿°­µµ¿°¿ë¾×
  • low-ionic-strength salt solution TEST = LISS test
    ÀúÀ̿°­µµ¿°¿ë¾×
  • magnetic field strength
    ÀÚÀå ¼¼±â, Àڱ⠰­µµ
  • marginal strength
    ¿¬º¯°­µµ(æÞܫ˭öô).
  • muscle force =m. strength
    ±Ù ·Â(ÐÉæ³).
  • peak gradient strength
    ÃÖ°í °æ»ç ¼¼±â
  • physical strength
    ü·Â(ô÷æ³).
  • shearing strength
    Àü´Ü°­µµ(¡­Ë­öô).
  • strength
    °­µµ(Ë­öô), Èû, ¼¼±â.
  • strength duration curve
    °­µµ-±â°£°î¼±(Ë­ öôÑ¢ÊàÍØàÊ).
  • strength test
    °­µµ°Ë»ç
  • tearing strength
    Àο­µµ(ìÚæñöô).
  • tensile strength
    ½ÅÀå°­µµ(ãßíåË­öô).
  • tensile strength
    ½ÅÀå°­µµ(ãßíåË­öô)
  • tinting strength
    Âø»ö·Â(ó·ßäæ³).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • "Monod, Wyman, and Changeux model"
    ¸ð³ë.¿ÍÀ̸¸.¼§Á¶¸ðµ¨
  • Park and Johnson method
    ÆÄÅ© Á¸½¼ ¹ý(Ûö)
  • patch and cut repair
    Àý´Ü ºÎ ¼öº¹(ï·Ó¨Ý¾áóÜÖ)
  • stem-and-loop DNA
    ÁÙ±â- ·çÇÁ DNA
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SRD service-related disability; Society for the Relief of Distress; Society for the Right to Die; sodium...
UNDRO United Nations Disaster Relief Organization
WMR work metabolic rate; World Medical Relief
MCP maximum closure pressure; maximum contraction pattern; malanocortin receptor; melphalan, cyclophosph...
Dmax maximum denaturation; maximum diameter
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
FLU Flutamide
DTS Diametral tensile strength
ES Ego Strength
HGS Handgrip strength
IS Ionic Strength
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • maximum discrimination score
    ÃÖ´ë ¸í·áÄ¡
  • maximum expiratory flow rate
    ÃÖ´ë È£±â À¯·®·ü
  • maximum foundation plane
    ÀÇÄ¡»ó Æò±Õ Àú¸é
  • maximum intercuspal contact
    ÃÖ´ë ±³ÇÕ Á¢ÃË
  • maximum intercuspation
    ÃÖ´ë ±³µÎ°£À§, ÃÖ´ë ±³µÎ °¨ÇÕ, ÃÖ´ë ±³ÇÕ
    »ó, ÇÏ¾Ç Ä¡¾ÆÀÇ ±³µÎµéÀÌ °¡Àå ¸¹ÀÌ Á¢ÃËÇÏ´Â °Í.
  • maximum mid-expiratory flow rate
    ÃÖ´ë Áß°£ È£±â À¯Ãâ ¼Óµµ
  • maximum oxygen consumption
    ÃÖ´ë »ê¼Ò ¼Ò¸ð·®
  • maximum permissible concentration
    ÃÖ´ë Çã¿ë ³óµµ
  • maximum permissible exposure
    ÃÖ´ë Çã¿ë ³ëÃâ
  • maximum permissible limit
    ÃÖ´ë Çã¿ë ÇѰè
  • maximum point of opening
    ÃÖ´ë °³±¸À§
  • maximum rotation of the joint
    °üÀýÀÇ ÃÖ´ë ȸÀü ¿îµ¿·®
  • maximum security unit
    ÃÖ´ë ¾ÈÀü º´µ¿
  • maximum surgical blood order schedule
    ÃÖ´ë ¼ö¼ú Ç÷¾× ¿äû ¿¹Á¤Ç¥
  • maximum tolerance dose
    ÃÖ´ë ³»¿ë·®, ÃÖ´ë °ßµõ ¼±·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
ionic strength Symbolised as g/2 or I and set equal to 0.5σmizi2, where mi equals the molar concentration and zi the charge of each ion present in solution; if molar concentrations (ci) are used instead of molality (and the solution is dilute), then I == 0.5(1/ρo)σcizi2 where ρo is the density of the solvent; a number of biochemically important events (e.g., protein solubility and rates of enzyme action) vary with the ionic strength of a solution.
(05 Mar 2000)
tensile strength The maximum stress a material subjected to a stretching load can withstand without tearing.
(12 Dec 1998)
yield strength The amount of stress at which a permanent (plastic) deformation in a component becomes measurable (usually taken as 0.2% permanent strain).
(05 Mar 2000)
ultimate strength The maximum stress achieved prior to failure of a component on a single application of the load.
(05 Mar 2000)
fatigue strength The stress level below which a particular component will survive an indefinite number of load cycles (typically about 50% of the ultimate strength of the component).
(05 Mar 2000)
paroxysmal cold haemoglobinuria <haematology> A rare blood disorder caused by antibodies which destroy red blood cells upon exposure to the cold.
The antibodies are formed against a specific blood group and are triggered by the cold. The cause is unknown but the disease has been associated with syphilis and some viral infections. Serum haemoglobin and urine haemoglobin are increased during the attacks.
The disease is chronic and treatment is difficult. Some cases resolve spontaneously without treatment.
Origin: Gr. Ouron = urine
(27 Sep 1997)
rose cold Allergic rhinitis occurring in the spring and early summer.
(05 Mar 2000)
warm-cold haemolysin Haemolysin which combines with red blood cells at temperatures below 20°C and are eluted at warmer temperatures, e.g., 30 to 37°C.
See: Donath-Landsteiner cold autoantibody, haemagglutinating cold autoantibody.
(05 Mar 2000)
cold <virology> A slang term that describes a viral upper respiratory infection which results from inflammation of the mucous membranes of the nasal cavity.
(27 Sep 1997)
cold abscess An abscess without heat or other usual signs of inflammation.
Synonym: tuberculous abscess.
(05 Mar 2000)
cold agglutination The agglutination of red blood cells by their own serum (see autoagglutination), or by any other serum when the blood is cooled below body temperature, but most pronounced below 25°C; the phenomenon results from cold agglutinins; may be seen occasionally in the blood of apparently normal persons or as a pathologic finding in patients with primary atypical pneumonia, infectious mononucleosis, and other viral diseases, certain protozoan infections, or lymphoproliferative neoplasms.
See: autoagglutination.
(05 Mar 2000)
cold agglutination test <investigation> A test for blood antibodies which are present in certain peculiar types of pneumonia (atypical pneumonia, Mycoplasma)
(27 Sep 1997)
cold agglutinin An antibody which reacts more efficiently at temperatures below 37°C.
(05 Mar 2000)
cold agglutinins <haematology> Antibodies that agglutinate particles with greater activity below 32­C. They are IgM antibodies specifically reactive with blood groups I and i in humans and agglutinate red blood cells on cooling, causing Raynaud's phenomenon in vivo.
(18 Nov 1997)
cold allergy Physical symptoms produced by hypersensitivity to cold.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • clay-cold
    (½Ãü µî)Á¡Åäó·³ Âù;»ý¸íÀÌ ¾ø´Â
  • cold
    Ãß¿î;Âù;Â÷°¡¿î;½ÄÈù;½ÄÀº;³ÃÁ¤ÇÑ;³Ã´ãÇÑ;½Ò½ÒÇÑ;°´°üÀûÀÎ;ÈïÀ» ±ú´Â;¸¶À½ ³»Å°Áö ¾Ê´Â;(¸ÀÀÌ)¾àÇÑ;(¾Ë¾Æ ¸ÂÈ÷±â ³îÀÌ¿¡¼­)¾î¸²ÀÌ ºø³ª°£;Á»Ã³·³ ¸ÂÁö ¾Ê´Â;ÇÑ»öÀÇ(û»ö.ȸ»ö µî);(Áü½ÂÀÌ ³²±ä ³¿»õ°¡)Èñ¹ÌÇÑ;(¶¥ÀÌ)¿­À» Èí¼öÇϱ⠾î·Á¿î;ºÒ°¨ÁõÀÇ;(±¸Å¸ µîÀ¸·Î)±âÀýÇÏ¿©;Á×
  • cold blast
    (¿ë±¤·Î¿¡ ºÒ¾î ³Ö´Â)³Ãdz;Âù¹Ù¶÷ y
  • cold case
    ¸Å¿ì ³ª»Û »óȲ;±ÃÁö
  • cold cash
    Çö±Ý
  • cold chain
    Àú¿Â À¯Åë ü°è(»ý¼±.¾ßäµîÀ» ³ÃÀå,Àú¿Â »óÅ·Π°ø±ÞÇÔ)
  • cold chisel
    (±Ý¼Ó¿ë)Á¤
  • cold coil
    ³Ã°¢¿ë ÄÚÀÏ
  • cold colors
    ÇÑ»ö(û»ö.ȸ»öµî)
  • cold comfort
    ´Þ°©Áö ¾ÊÀº À§·Î
  • cold counsel
    ´Þ°©Áö ¾ÊÀº Á¶¾ð
  • cold cream
    ÄݵåÅ©¸²(È­ÀåÅ©¸²ÀÇ ÀÏÁ¾)
  • cold cuts
    ³ÃÀ°°ú Ä¡Áî·Î ¸¸µç ¿ä¸®
  • cold deck
    (¹Ù²ãÄ¡±â Çϱâ À§ÇÑ)ºÎÁ¤Ä«µåÀÇ ÇÑ ¹ú;(Á¦Á¦¼Ò·Î °¥)¹úä¼ÒÀÇ ½Æ´Ù ³²Àº Å볪¹«
  • cold drawing
    »ó¿Â¿¡¼­ Àâ¾Æ ´ÃÀ̱â
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á